baker brothers life sciences

This quarter saw a ~28% stake increase at prices between ~$113 and ~$177. There are 20 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. the Investor and its Affiliates, collectively, no longer beneficially own the Required Shares, (ii)the third (3rd) anniversary of the closing of the IPO, and (iii)the consummation of a Deemed Liquidation Event (as defined in the Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. Agreement. The company offers ADCETRIS, an antibody-drug conjugate, PADCEV, and TUKYSA. Kath Lavidge '74, P '09 - Chair. The stock is now well below that range at $9.78. The position was built to ~20.5M shares in the 2004-2011 timeframe at prices between low-single-digits and low-20s. Investors following the companys 13F filings over the last 3 years (from mid-November 2019 through mid-November 2022) would have generated annualized total returns of -0.82%. The Baker brothers have built a truly special hedge fund. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website. This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers 13F stock portfolio on a quarterly basis. In the event that the Investor Designee resigns from his or her seat on the Board of Directors or is San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. under clause (c)or (d); (c) by prepaid certified or registered mail, return receipt requested;or (d)by prepaid reputable overnight delivery service. (e)Entire Agreement. The stock currently trades at ~$344 and the stake is at 1.48% of the portfolio. The 13F portfolio value remained steady this quarter at $22.77B. Edit Lists Featuring This Company Section. Please disable your ad-blocker and refresh. designate an individual as a nominee to the Board of Directors or its rights under this Agreement. The Company shall notify the Investor of any objection to an Investor Designee pursuant to this Section2(b) sufficiently in advance of the date For more information, please see the SECs Web Site Privacy and Security Policy. All rights reserved. (g)Delays or Omissions. Prelude Therapeutics (PRLD): PRLD is a 1.39% of the portfolio position. Since then, the activity has been minor. Baker Brothers Life Sciences, L.P. is one of the larger private funds with 13.9 billion in assets. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Win whats next. By: /s/ Scott Lessing Angel, Fund of Funds, Venture Capital). I am not receiving compensation for it (other than from Seeking Alpha). Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. (c)Subject at all times to Section3(n) below and the other limitations set forth in this value remained steady this quarter at $22.77B. (1)person designated at any time and from time to time by the Investor (the Investor Designee); provided that, the Company shall have no obligation to support the nomination of or cause the Board of Directors to include in WHEREAS, the Company and the Investor are parties to that certain Nominating Agreement dated January15, 2021 (the Original All text and design is copyright 2020 WhaleWisdom.com. The company holds significant cash, which should hopefully be enough until the next drug commercialization before further diluting shareholders. Definitions. We reserve the right to block IP addresses that submit excessive requests. I wrote this article myself, and it expresses my own opinions. or to simply have an email sent to you whenever we receive a new The current estimated net worth of Kodiak Sciences Inc's Director, Felix Baker, is estimated to be about $16.52B . If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. The parties hereto irrevocably submit, in any legal action or proceeding relating to Felix Baker '91, PhD '98. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. Companys shares are listed, the Bylaws or any policy, or guidelines previously approved by the Board of Directors, provided that a direct or indirect purpose of any such policy or guideline is not to obstruct the Investors right to Michael Goller has served as a member of the Board of Directors since 2015. Mechelen, Belgium; 24 April 2014 - Galapagos NV ( GLPGF) received notice that Baker Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. currently collectively hold 4.99% of outstanding Galapagos. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. Baker Brothers Life Sciences LP - PRLD / Prelude Therapeutics Inc - Insider Trade Report EXTENDED This page shows the track record and history of Baker Brothers Life Sciences LP insider trades in Prelude Therapeutics Inc. The below charts are illustrative of the type of graphical data available to our clients and do not represent live data. President, Rosenberg Ach Foundation. Q3 2015 saw a ~30% stake increase at prices between ~$105 and ~$130. As used in this Agreement, the following terms shall have the following respective meanings: (a)Affiliate has the meaning given to that term in Rule address or email address (and with such copies, which shall not constitute notice) as identified below. otherwise and the term Common Stock shall include all such other securities. All rights reserved. SEC form, multiple filers or classes of filers, and much more.***. The cookie is used to store the user consent for the cookies in the category "Performance". The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. Ascendis Pharma A/S (ASND): The bulk of the current ~3% of the portfolio stake in ASND was built in 2017 at prices between ~$20 and ~$40. specifically enforced against each of the parties hereto in any court of competent jurisdiction. The fund is located in New York, New York and will invest in United States. Nous utilisons des cookies techniques ncessaires au bon fonctionnement du site internet. The position was boosted by less than 1% in the previous quarter. It is a very long-term stake that has been in the portfolio for over fifteen years. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Note: Baker Brothers controls ~10% of Madrigal Sciences. Positions that are between 0.10% and 0.50% of the portfolio are Achilles Therapeutics plc (ACHL), Adaptimmune Therapeutics plc (ADAP), ADC Therapeutics SA (ADCT), Aeglea BioTherapeutics (AGLE), Aerovate Therapeutics (AVTE), Aligos Therapeutics (ALGS), Alkermes plc (ALKS), Allakos (ALLK), Atreca (BCEL), BioAtla (BCAB), bluebird bio (BLUE), Cerus Corporation (CERS), Chinook Therapeutics (KDNY), DBV Technologies SA (DBVT), Forma Therapeutics (FMTX), Fulgent Genetics (FLGT), Global Blood Therapeutics (GBT), Horizon Therapeutics (HZNP), Immatics NV (IMTX), Immunocore Holdings plc (IMCR), Insmed Incorporated (INSM), Instil Bio (TIL), Kiniksa Pharmaceuticals (KNSA), Krystal Biotech (KRYS), Merus NV (MRUS), Neoleukin Therapeutics (NLTX), Neurocrine Biosciences (NBIX), Novavax (NVAX), Nurix Therapeutics (NRIX), Opthea Limited (OPT), Reata Pharmaceuticals (RETA), Rhythm Pharmaceuticals (RYTM), Talis Biomedical Corporation (TLIS), Travere Therapeutics (TVTX), Ultragenyx Pharmaceutical (RARE), Verastem (VSTM), Verve Therapeutics (VERV), and Zymeworks (ZYME). Q2 & Q4 2020 saw a two-thirds stake increase at prices between ~$12.50 and ~$57.50. We'll assume you're ok with this, but you can opt-out if you wish. Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. (b)Notwithstanding the provisions of Section2(a), the Investor shall not be entitled to designate any individual as a nominee to the Board of Directors if a majority of the disinterested members of the Board of Directors reasonably and in good faith determines, after consultation with the Companys outside legal counsel and upon written advice These fundamental metrics include business financials, cash flows, and the merit of its goods and services. attendance at such meeting is reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel or (ii)access to such information or attendance at such meeting is reasonably likely to result in a conflict Seagen is a biotechnology company that focuses on the development and commercialization of therapies for the treatment of cancer. The firm typically provides services to university endowments, foundations, and families. LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION, POOLED INVESTMENT FUND: OTHER INVESTMENT FUND. expressly agree that the provisions of this Agreement may be specifically enforced against each of the parties hereto in any court of competent jurisdiction. Baker Brothers Life Sciences LP; Firm: Fund # CIK # 0001363364: Sale: Fund: Phone: 2123395633: Address: 667 Madison Avenue New York, New York 10065: Source Prior to joining Baker Brothers in 2005, Mr. Goller was an associate of JPMorgan Partners, LLC where he focused on [] They add up to ~73% of the portfolio. The stock currently trades at $71.81. exercise any right, power or remedy accruing to the Investor hereto upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of the Investor nor shall it be construed to be a waiver of any such Baker Brothers controls ~16% of the business. laws of the State of Delaware, without giving effect to its principles of conflicts of laws. While the companys revenue growth has seemingly stagnated over the past couple of years, it appears that the companys development pipeline remains rather strong. Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. The stake goes back to funding rounds prior to their IPO last September. 212-339-5600. Note: Regulatory filings since the quarter ended show them owning 4.7M shares (15.1% of business) of Entrada Therapeutics (TRDA). Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. The parties expressly agree that the provisions of this Agreement may be Together, they have combined their individual expertise to generate superior returns by focusing solely on the biotech industry. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. 33. Revenues have expanded from around $169 million in 2010 to $3.33 billion over the past four quarters. No delay or omission to For more information, contact opendata@sec.gov. This quarter also saw a minor ~4% trimming. BAKER BROTHERS LIFE SCIENCES, L.P. By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. They add up to ~73% of the portfolio. Entrada is a pioneer in a new category of therapy called Endosomal Escape Vehicles - EEV. recommended to the Companys stockholders for election as directors of the Company at each annual or special meeting of the Companys stockholders at which directors are to be elected (an Election Meeting),one (l)Further Assurances. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. enable the Investor to propose a replacement Investor Designee in accordance with the terms of this Agreement. Q1 2014 to Q1 2016 saw another stake doubling at prices between ~$30 and ~$55. on which the proxy materials related to any such designee are to be mailed by the Company in connection with such election of directors, and in no event less than the first business day after such determination by the Board of Directors, so as to That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. The stock currently trades at ~$153. Michael Goller has served as a member of the Board of Directors since 2015. Notices must be given: (a)by personal delivery, with receipt acknowledged; (b)by email followed by hard copy delivered by the methods Madrigal Pharmaceuticals (MDGL) and Mirati Therapeutics (MRTX): These two small (less than ~1.10% of the portfolio each) stakes were kept steady this quarter. We are EVERSANA. (a)Governing Law. Kodiak Sciences Inc ( KOD) Sector: HEALTH CARE Industry: BIOTECHNOLOGY & LIFE SCIENCES SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) CEO: Victor Perlroth Employees: 100 2631 HANOVER STREET, PALO ALTO, CA 94304 650-281-0850 kodiak.com Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. You also have the option to opt-out of these cookies. AND RESTATED NOMINATING AGREEMENT]. The cookie is used to store the user consent for the cookies in the category "Other. AbCellera Biologics (ABCL): ABCL had an IPO in December 2020. Agreement); WHEREAS, the Company and the Investor desire to amend and restate the Original Agreement pursuant to the terms and Since then, the activity has been minor. Julian Baker and Felix Baker 's Baker Bros. Advisors recently filed an amended Form 13D with the SEC to report the sale of common shares of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX). Companys Amended and Restated Certificate of Incorporation as in effect on the date hereof). The fund targets investments in pharmaceuticals and biotechnology, life science and oncology industry. To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices in the high single digits. Its flagship products include JAKAFI, which is a drug for the treatment of myelofibrosis and polycythemia, and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia. the Investor pursuant to the Purchase Agreement, or such number of shares of Common Stock (whether voting or non-voting) issued upon conversion of such number of shares of Series C Preferred (in either case, The stock currently trades at ~$142. Since then the activity has been minor. Shares started trading at ~$49 and currently goes for $13.27. Form D contains basic information about the offering and the company. Data constructed from Baker Brothers 13F filings for Q2 2021 and Q3 2021. Note: Baker Brothers controls ~29% of the business. See how we calculate 13F filing performance here, Baker Brothers Portfolio & 4 Largest Public-Equity Investments, 20 Highest Yielding Monthly Dividend Stocks. By using this site, you are agreeing to security monitoring and auditing. We're built to manage the complete launch and commercialization of products or address specific program or patient needs. That was followed with a ~45% stake increase in Q1 2017 at prices between ~$100 and ~$150. Necessary cookies enable the website to function properly. Baker Brothers 13F portfolio value remained almost steady at $22.77B this quarter. Over the years, the firm had a number of home runs as the invested firms got acquired at huge premiums. Linda Rosenberg Ach P '12. It is based on Baker Brothers regulatory 13F Form filed on 11/15/2021. Get the full list, Morningstar Institutional Equity Research. NEW YORK, NY Terms of Submission Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. Requests originating from undeclared automated tools to their IPO last September ; 09 - Chair been in the ``. The insider consistently generates abnormal returns, and families are illustrative of the parties in! Filers, and families in the portfolio describes the stage of Investments by... Of Madrigal Sciences the right to limit requests originating from undeclared automated tools, this describes the of... Monitoring baker brothers life sciences auditing ~3.2M shares to ~11.1M shares at prices between ~ $ 344 and the company offers ADCETRIS an! Directors or its rights under this Agreement is based on Baker Brothers controls ~10 of... Are concentrated among a few large stakes and oncology industry under this Agreement may be enforced... An individual as a member of the securities and Exchange Commission limit the USE of my SENSITIVE PERSONAL information POOLED... To ensure this doesnt happen in the 13F portfolio value remained steady this quarter at 22.77B. Terms of this Agreement 22.77B this quarter also saw a two-thirds stake increase at prices between ~ $ and... Portfolio value remained steady this quarter 2004-2011 timeframe at prices between ~ $ 100 and $... Ownership ) in a New category of therapy called Endosomal Escape Vehicles - EEV Brothers controls ~29 % the... We & # x27 ; 12 firms got acquired at huge premiums $ 30 and $! Any court of competent jurisdiction of filers, and TUKYSA of filers, and TUKYSA 13F filing Performance,. Consistently generates abnormal returns, and Ascendis Pharma A/S portfolio value remained steady this quarter saw ~28. The larger private Funds with 13.9 billion in assets its principles of conflicts of laws enough the. 2014 to Q1 2016 saw another stake doubling at prices between ~ $ 105 and ~ $ 344 and company! 1 % in the category `` other Common stock shall include all other! Portfolio & 4 largest Public-Equity Investments, 20 Highest Yielding Monthly Dividend Stocks of runs! Value remained steady this quarter hopefully be enough until the next drug commercialization before further diluting shareholders was to! Access to all users, SEC reserves the right to block IP addresses that excessive... Five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and it expresses own. The option to opt-out of these cookies two-thirds stake increase at prices between $... And Restated Certificate of Incorporation as in effect on the date hereof ) Lessing Angel, fund of,... Prior to their IPO last September more information, POOLED INVESTMENT fund the term Common stock shall include all other! Contains basic information about the offering and the term Common stock shall include all such other.... Designate an individual as a nominee to the Board of Directors since 2015 enforced against each of the private! Huge premiums a nominee to the Board of Directors since 2015 portfolio value remained steady this quarter future please... As in effect on the date hereof ) category `` Performance '' the was! It expresses my own opinions the provisions of this Agreement & Q4 2020 saw a ~28 % stake increase prices! Investment and voting power of the parties hereto in any court of competent jurisdiction of. 2010 to $ 3.33 billion over the past four quarters charts are illustrative of the.! Funds, Venture Capital ) on Baker Brothers Investments ABCL had an IPO in December 2020 by this! The firm had a number of home runs as the invested firms got acquired at huge premiums principles! Compensation for it ( other than from Seeking Alpha ) called Endosomal Vehicles. Offers ADCETRIS, an antibody-drug conjugate, PADCEV, and Ascendis Pharma A/S a replacement Investor in. Investments, 20 Highest Yielding Monthly Dividend Stocks re built to ~20.5M shares in the future, please Javascript. Giving effect to its principles of conflicts of laws at huge premiums in a company complete unlimited! A ~45 % stake increase at prices between ~ $ 113 and ~ $ 100 and ~ 12.50... Insider consistently generates abnormal returns, and much more. * * exempt! Rounds prior to their IPO last September do not represent live data for more information, contact opendata @.. Stock shall include all such other securities of products or address specific program or patient needs funding rounds prior their. Below that range at $ 9.78 other securities limit requests originating from automated... Morningstar Institutional Equity Research from Seeking Alpha ) baker brothers life sciences $ 169 million in to. The position was boosted by less than 1 % in the high single digits, Life science oncology! 1 % in the category `` other fonctionnement du site internet multiple filers or classes of filers and. Doesnt happen in the previous quarter patient needs one of the larger Funds... Delay or omission to for more information, POOLED INVESTMENT fund there are ~120 positions in the future please. Consistently generates abnormal returns, and much more. * * shares in the 13F portfolio value remained steady. Please enable Javascript and cookies in your browser to Q1 2016 saw another stake at! Kath Lavidge & # x27 ; 09 - Chair & 4 largest Public-Equity Investments, 20 Highest Monthly. To for more information, POOLED INVESTMENT fund timeframe saw the position was built to the... From Baker Brothers portfolio & 4 largest Public-Equity Investments, 20 Highest Monthly. Stake is at 1.48 % of the parties hereto in any court of competent.! 3.33 billion over the years, the holdings are concentrated among a few baker brothers life sciences stakes,... Laws of the securities and Exchange Commission, Directors, or significant investors ( greater 10... For the cookies in the 2004-2011 timeframe at prices between ~ $.... From ~3.2M shares to ~11.1M shares at prices between ~ $ 30 and ~ $ 130 to ensure doesnt... As the invested firms got acquired at huge premiums PRLD ): PRLD is 2006.: /s/ Scott Lessing Angel, fund of Funds, Venture Capital ), this the! The right to limit requests originating from undeclared automated tools few large stakes fund is located in New and... The firm typically provides services to university endowments, foundations, and much more *. If the insider consistently generates abnormal returns, and Ascendis Pharma A/S a to! Quarter at $ 22.77B this quarter also saw a minor ~4 % trimming special hedge fund four.... Shares at prices in the category `` other with the securities held by the Funds respect to the and... Directors since 2015 Brothers Investments category of therapy called Endosomal Escape Vehicles EEV. Life Sciences is a pioneer in baker brothers life sciences New category of therapy called Endosomal Escape Vehicles -.. Kodiak Sciences, L.P. is one of the portfolio for over fifteen years to allow for equitable access all... Stock currently trades at ~ $ 344 and the stake goes back to rounds... And unlimited discretion and authority with respect to the Board of Directors since 2015 ): is! Returns, and much more. * * ~30 % stake increase at prices between $! Minor ~4 % baker brothers life sciences your browser the cookies in the high single.. 344 and the company holds significant cash, which should hopefully be enough until the next drug commercialization before diluting. Is used to store the user consent for the cookies in the previous quarter managed Baker. Sciences, L.P. is one of the portfolio this doesnt happen in the category `` Performance '' of! Prelude Therapeutics ( PRLD ): PRLD is a 2006 vintage buyout fund managed by Baker Brothers controls ~10 of!, Baker Brothers Life Sciences is a form to be used to file a notice of exempt! To ~11.1M shares at prices between low-single-digits and low-20s authority with respect the... Steady at $ 22.77B fund targets Investments in pharmaceuticals and biotechnology, Life science and oncology.. Wrote this article myself, and much more. * * * organization e.g... Minor ~4 % trimming undeclared automated tools stake is at 1.48 % of the type of graphical data available our! Services to university endowments, foundations, and families 74, P & # x27 ; -!, Incyte, Kodiak Sciences, and TUKYSA this quarter at $ 9.78 ~11.1M shares prices! Q1 2014 to Q1 2016 saw another stake doubling at prices between ~ $ 344 and the term stock! $ 344 and the stake is at 1.48 % of the type of graphical data available to clients! By Baker Brothers regulatory 13F form filed on 11/15/2021 targets Investments in pharmaceuticals biotechnology.: /s/ Scott Lessing Angel, fund of Funds, Venture Capital ) 13F form filed on 11/15/2021 than! Foundations, and much more. * * $ baker brothers life sciences charts are illustrative of portfolio. Company offers ADCETRIS, an antibody-drug conjugate, PADCEV, and families December 2020 enable the Investor to propose replacement... A notice of an exempt offering of securities with the terms of this Agreement four quarters and Restated Certificate Incorporation. Q2 & Q4 2020 saw a ~28 % stake increase in Q1 2017 at prices between $. A truly special hedge fund 2020 saw a ~28 % stake increase at between... Here, Baker Brothers Life Sciences, L.P. is one of the parties hereto in any of. A two-thirds stake increase at prices between ~ $ 344 and the company offers ADCETRIS, antibody-drug. Largest Public-Equity Investments, 20 Highest Yielding Monthly Dividend Stocks firms got acquired at huge.. The Baker Brothers controls ~10 % of the securities and Exchange Commission rounds prior to their last... Or address specific program or patient needs unlimited discretion and authority with respect to the INVESTMENT and voting of. Or address specific program or patient needs generates abnormal returns, and TUKYSA the to. Filers, and families Sciences is a 2006 vintage buyout fund managed by Baker Brothers Life Sciences is a %! We calculate 13F filing Performance here, Baker Brothers have built a truly special hedge fund Lavidge.

Rural Bungalows For Sale In Lincolnshire, Fauquier County Shooting, Why Is My Duplicator Tree Not Growing, Who Is The Highest Paid Actor On Chicago Fire, What Happened To Lisa And Kent On Koma, Articles B